Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients
Authors:
- Begoña JiménezBJBegoña Jiménez
- José M. TrigoJTJosé M. Trigo
- Bella I. PajaresBPBella I. Pajares
- Maria I. SáezMSMaria I. Sáez
- Cristina QueroCQCristina Quero
- Victor NavarroVNVictor Navarro
- Casilda LlácerCLCasilda Llácer
- Laura MedinaLMLaura Medina
- Antonio RuedaARAntonio Rueda
- Emilio AlbaEAEmilio Alba
- 1 February 2013
- journal article
- Published by Elsevier in Oral Oncology
- Vol. 49 (2) , 182-185
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neckAnnals of Oncology, 2011
- Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimensOral Oncology, 2010
- Recurrent head and neck cancer: current treatment and future prospectsExpert Review of Anticancer Therapy, 2008
- Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancerAnti-Cancer Drugs, 2007
- Single-agent Docetaxel in Patients with Platinum-refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)Japanese Journal of Clinical Oncology, 2007
- Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based TherapyJournal of Clinical Oncology, 2007
- Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) ProgramThe Oncologist, 2007
- Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2005
- Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2005
- Second-line treatment with docetaxel after failure of a platinum-based chemotherapyin squamous-cell head andneck cancerAnnals of Oncology, 2002